Action CATX PERSPECTIVE THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Perspective Therapeutics, Inc.

Actions

CATX

US46489V1044

Marché Fermé - Nyse
Autres places de cotation
 22:00:00 28/05/2024 		Varia. 5j. Varia. 1 janv.
1,56 USD +4,00 % Graphique intraday de Perspective Therapeutics, Inc. -1,89 % +288,06 %
24/05 Perspective Therapeutics fixe le prix de son offre d'actions et de bons de souscription à 80 millions de dollars MT
15/05 Transcript : Perspective Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Perspective Therapeutics Prices $80 Million Share, Warrant Offering
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
Perspective Therapeutics, Inc. Announces the Selection of Investigational Product VMT-a-NET for the Treatment of Certain Patients with Neuroendocrine Tumors by the U.S. Food and Drug Administration to Participate in the Chemistry
Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.
Perspective Therapeutics : Unaudited Pro Forma Condensed Consolidated Financial Information - Form 8-K
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CATX
  4. Actualités Perspective Therapeutics, Inc.
  5. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT